Clinical Trial Update: Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 neoadjuvant trial is evaluating axitinib plus a PD-1 inhibitor to improve disease-free survival in patients with renal cell carcinoma and is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• PD-1 inhibitor

Snippet

Sponsor: ZHOU FANGJIAN | Conditions: Renal Cell Carcinoma, Neoadjuvant | Phase 3 | Status: RECRUITING